Envestnet Asset Management Inc. Has $781.31 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Envestnet Asset Management Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,711,203 shares of the company's stock after acquiring an additional 168,535 shares during the quarter. Envestnet Asset Management Inc. owned about 0.20% of Johnson & Johnson worth $781,306,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Roffman Miller Associates Inc. PA raised its position in Johnson & Johnson by 0.8% in the first quarter. Roffman Miller Associates Inc. PA now owns 263,418 shares of the company's stock worth $43,685,000 after purchasing an additional 2,020 shares in the last quarter. Hexagon Capital Partners LLC raised its stake in Johnson & Johnson by 1.4% during the first quarter. Hexagon Capital Partners LLC now owns 6,755 shares of the company's stock worth $1,120,000 after acquiring an additional 96 shares in the last quarter. Drake & Associates LLC lifted its holdings in shares of Johnson & Johnson by 54.1% during the first quarter. Drake & Associates LLC now owns 14,896 shares of the company's stock valued at $2,470,000 after acquiring an additional 5,227 shares during the period. Traveka Wealth LLC boosted its stake in shares of Johnson & Johnson by 21.7% in the 1st quarter. Traveka Wealth LLC now owns 7,749 shares of the company's stock valued at $1,285,000 after purchasing an additional 1,382 shares in the last quarter. Finally, Tradewinds LLC. lifted its holdings in Johnson & Johnson by 2.4% during the 1st quarter. Tradewinds LLC. now owns 18,102 shares of the company's stock valued at $3,002,000 after purchasing an additional 429 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Raymond James Financial dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.2%

Shares of Johnson & Johnson stock traded up $0.28 during trading hours on Wednesday, reaching $156.07. 6,140,694 shares of the company's stock were exchanged, compared to its average volume of 8,058,336. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $153.67 and a two-hundred day moving average of $154.25. The stock has a market cap of $375.52 billion, a P/E ratio of 17.36, a P/E/G ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.33%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.